We hope everyone has a pleasant weekend. Here at Blue Horseshoe Stocks, we are already looking forward to next week, as we will be releasing a new pick that has us really excited!
Consider this a reminder to check back with us regularly over the next few trading days.
Stay Safe & Stay Tuned!
-Blue Horseshoe
&
We released CSOC as a momentum alert on Nov. 7th. Since that time, we caught a low at .054, meaning today’s high of .09 represents a 66% gain in just four days’ time.
We had previously drawn parallels between CSOC and our last momentum play, MILV, noting that “We are not getting impatient with CSOC, as sometimes it takes several days for many of our plays to develop as in the case of MILV.” -Our Newsletter for Nov.9th
We promise, we don’t have the power to see the future, it just seems that way sometimes!
We first alerted MILV at .055, followed by a dip to .047, subsequently hitting a high of .142. That’s a total possible gain of 202% during a process which took about two weeks. At present, our alert of CSOC is only about four days old, thus the next week and a half will tell the story of how close CSOC can come to MILV’s accomplishment.
We are seldom late to the party, and in the case of PROT, it appears we are a bit early. A reader pick, PROT, has the look of a stock that could rock at any moment. At the moment, things are pretty quiet, but with this technically sound chart, any small amount of buying pressure could kick into motion one heck of a run.
______________________
A retesting of this past Summer’s highs would mean added gains on the order of 100% or more.
In a recent press release, the company alluded to its plans to test its stem cell treatments overseas, where the costs and barriers associated with introducing such treatments are far lower. A figurative and literal testing ground before attempting to enter the American market.
MOUNTAINSIDE, NJ, Oct 19, 2011 (MARKETWIRE via COMTEX) — PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that it intends to move forward with the testing of its StromaCel technology through its PRTMI subsidiary or its affiliates. The Company decided to examine the possibility of testing its cardiac stem cell treatment offshore in light of the progress toward its trial of UMK-121, its stem cell treatment for patients awaiting liver transplant to overcome End Stage Liver Disease (“ESLD”), in the United States.
Michael Cohen, President of the Company, stated: “Since we progress toward the commencement of our trial of UMK-121 in the United States, we have decided to explore the possible testing of our cardiac treatment offshore in order to reduce the cost of bringing the cardiac treatment to market. This strategic decision is being made in recognition of the increasing costs associated with bringing a new drug to market in the United States through the NDA (New Drug Application) process and the availability of expert medical testing capabilities offshore at a fraction of the cost.”
______________________
ATTENTION READERS!
We will be introducing a brand new play next week, so don’t forget to pay close attention! We are really excited about what we think this stock can do in the next few weeks!
CSOC traded just as we predicted in yesterday’s report. There was a small premarket gap up from .071 to .072, followed by a dip to .0623 followed by a close at .069 for an 11% intraday gain.
We are not getting impatient with CSOC, as sometimes it takes several days for many of our plays to develop as in the case of MILV.
BIRMINGHAM, England, Nov 08, 2011 (BUSINESS WIRE) — Caduceus Software Systems Corp. (OTCBB: CSOC) – (The Company) is pleased to announce that it will be offering a 30-day Free trial of the Caduceus MMS Software System to 1,000 specially chosen customers in the medical community of the UK.
These customers will have the option of purchasing the fully licensed version of the software after the completion of the complimentary 30-day trial.
Using this newly proposed marketing strategy will prove very beneficial to Caduceus Software Systems (CSOC). The goals CSOC plans to achieve using this strategy include a complete marketing survey outlining retention and licensing statistics.
MILV was trading at .055 when we introduced it to our our readers as a momentum play. Following the alert, it hit a high of .0739 (+34%), before dipping back to .047.
We continued to cover the play, and have now witnessed a new high as the stock traded on up to .142 yesterday! That’s an added 202% percent on top of the 34% on the first swing, bringing our total gains for this stock to 236% in just under two weeks. Very impressive.
EXTO has undergone a consolidation after its run from .004 to .0082, now resting at a base of .006.
The stock has shown us its ability to rattle off explosive gains, and quite rapidly at that, so one must keep a watchful eye to catch the next wave. We will of course monitoring and reporting its status to you as always.
CSOC was a good momentum call for us Monday midday. Following our call just before noon, .0625 to .0735 for a quick 18% gain.
We are going to be looking for similar trading activity today, starting with a possible premarket gap-up this morning. We will then look for a subsequent dip, and the opportunity to time the resultant bottom.
BIRMINGHAM, England–(BUSINESS WIRE)– Caduceus Software Systems Corp. (OTCBB:CSOC.ob – News) – (The Company) is pleased to announce that it has established and secured the team of Sygnit Corp., to act as software advisor for the Company. MORE>>
DGHG hit a new high of 1.29 on Monday, something that we had been calling for following the company’s uplisting to the OTCBB.
We feel that there is room for the stock to run further, with the RSI currently in the Power Zone.
This could be another play primed for a morning gap-up. The open could come at 1.30 or higher.
We have been on DGHG since late September and have seen gains of over 80% as the stock ran from .71 to the current price.
Get Our FREE Daily Reports!
